Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/26—Iron; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants

Definitions

• the invention relates to the use of iron (III) oxide in the case of immune deficiency, in particular aquired immune deficiency syndrome (AIDS) or against immune deficiency caused by the human immunodeficiency virus (HIV).
• AIDS aquired immune deficiency syndrome
• HIV human immunodeficiency virus
• the object of the invention is to provide a preferably orally administrable, non-toxic medicament with an antiviral effect, which can be safely administered to humans and animals after detection of a cellular immune deficiency and the dosage is not a criterion.
• this fully tolerable and side effect-free drug should be used as a prophylaxis against most diseases caused by viruses.
• Serological examinations have pien with iron (III) oxide with the exclusion of any side effects led to the following results:
• Virus detection HIV-I negative; Antigen detection HIV-I negative; Antibody positive.
• a rapidly developing product from an iron compound as a result of absorption of orally administered iron (I ⁇ I) oxide, e.g. Hemoglobin leads to the accumulation of the molecular cell structure in the organism without having to fear stressful connections with the stomach acid when taking this basic / active substance. Because of this behavior because of the insolubility of iron (III) oxide towards acids, the administration of this compound does not conflict with the physique.
• the iron (III) oxide was sterilized by heating in an autoclave (134 ° C., 60 min.) And suspended in culture medium after cooling. Aliquots of this suspension were mixed with phytohemagglutinin-activated lymphocytes from peripheral blood or from umbilical cord blood (final concentration 500,000 cells per ml) and incubated for 24 hours in an incubator at 37 ° C / 6% CO2. The cultures were then infected with the various HIV-1 and HIV-2 isolates shown in Table 1.
• Positive controls experimentation without iron (III) oxide with activated umbilical cord ymphocytes or PBL, which were infected with the various HIV-1 and HIV-2 isolates.
• Negative controls experimentation with uninfected cells or their culture supernatants.
• the cultures were assessed daily in a light microscope (examination for the development of a cytopathic effect (CPE) and by measurement of the retrovirus-specific enzyme reverse transcriptase (RT).
• CPE cytopathic effect
• RT retrovirus-specific enzyme reverse transcriptase
• Table 2 summarizes the light microscopic assessment of the cultures from three experiments carried out in parallel with PBL and one experiment with umbilical cord ymophocytes. They mean: - no visible cytopathic effect + visible cytopathic effect
• Table 2 Assessment of cell cultures for the formation of syncytia (CPE) on day 4 with activated umbilical cord lymphocytes or on day 6 with activated PBL.
• CPE syncytia
• Iron (III) oxide virus isolate concentration ( ⁇ g / ml) K31 D34 LAV-2 D194
• RT reverse transcriptase
• the enzyme activity is a rough measure of the amount of virus in the supernatant of the cells, however not identical to the amount of infectious virus particles. It is determined by incorporating radioactive thymidine into the DNA. The results of this experiment are therefore given in cpm / ml culture supernatant per 90 minutes.
• Table 3 Evaluation of the cell cultures (PBL) on the enzyme activity of the reverse transcriptase (cpm / ml per 90 min.) Eight days after the infection.
• Iron (III) oxide virus isolate concentration ( ⁇ g / ml) K31 D34 LAV-2 D194
• Iron (III) oxide in fine-grained form and / or its hydrate is used as the starting material for the production of suitable medicaments.
• the iron (III) oxide can be prepared as such or in the form of uninvolved, non-toxic, solid or liquid extenders or carriers, which are in solid or liquid form, e.g. capsules, coated tablets, microcapsules, suppositories, suspensions, emulsions can be used.
• the p.o.-usable preparations such as capsules or coated tablets are to be preferred.
• the production takes place in a manner known per se.
• iron (III) oxide to be administered largely depends on the field of application and the type of formulation. Included in the following subsequent examples
• a preferably stomach-soluble gelatin capsule 400 milligrams of fine-grained iron (III) oxide with a grain size of approximately 5 micrometers, intended for daily therapy by oral application in the case of immunodeficiency or

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Virology (AREA)
• Immunology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Molecular Biology (AREA)
• Tropical Medicine & Parasitology (AREA)
• AIDS & HIV (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Inorganic Chemistry (AREA)
• Epidemiology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=6520801

Family Applications (1)

Country Status (3)

Cited By (4)

Citations (4)

Family Cites Families (3)

• 1994
  • 1994-06-20 DE DE4421159A patent/DE4421159C1/de not_active Expired - Fee Related
• 1995
  • 1995-06-19 JP JP8501466A patent/JPH10507157A/ja active Pending
  • 1995-06-19 WO PCT/DE1995/000758 patent/WO1995035113A1/de active Application Filing

Patent Citations (4)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events